A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2017
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms FALCON
- Sponsors Blue Earth Diagnostics
- 26 Sep 2017 According to a Blue Earth Diagnostics media release, full results of this study will be available in a future peer reviewed publication.
- 26 Sep 2017 Data from a pre-planned interim analysis of this trial published in a Blue Earth Diagnostics Media Release.
- 26 Sep 2017 According to a Blue Earth Diagnostics media release, Status changed from active, no longer recruiting to suspended following successful results of a pre-planned interim analysis.